Tuesday, January 26WE ACCEPT QUALIFIED GUEST POSTS

Tag: WALTHAM

Thermo Fisher, Innoforce Partner Mfg. in China
Business

Thermo Fisher, Innoforce Partner Mfg. in China

Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China WALTHAM, MA and SHANGHAI (STL.News)  Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and Innoforce, a bioinnovation-enabling company, today announced they have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing.  The new facility is expected to be completed in 2022. The new state-of-the-art Good Manufacturing Practices (GMP) facility will become part of Thermo Fisher's extensive global pharma services network, which includes leading capabilities for drug product development, biologics manufacturing, sterile fill-finish, cli...
PerkinElmer to Acquire Cell Engineering Horizon Discovery
Business

PerkinElmer to Acquire Cell Engineering Horizon Discovery

PerkinElmer to Acquire Cell Engineering Horizon Discovery for $383 Million WALTHAM, MA (STL.News) PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Horizon Discovery Group plc (LSE: HZD) (“Horizon”) are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire Horizon for approximately $383 million (£296 million).  The transaction has a total enterprise value of approximately $368 million (£284 million), is expected to close in the first quarter of 2021 subject to customary closing conditions. With this investment, PerkinElmer will expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and gene modulation tools.  The acquisition will enable PerkinE...
Thermo Fisher Scientific Reports Third Quarter 2020 Financial Results
Business

Thermo Fisher Scientific Reports Third Quarter 2020 Financial Results

Third quarter revenue increased 36% to $8.52 billion. Third quarter GAAP diluted earnings per share (EPS) increased 157% to $4.84. Third quarter adjusted EPS increased 91% to $5.63. WALTHAM, MA (STL.News) Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2020. Generated $2.0 billion of COVID-19 related revenue in the quarter and returned the base business to growth. Further expanded our global pandemic response, including launching the Amplitude Solution to automate high-throughput PCR-based testing, adding significant capacity for viral transport media production in Europe and introducing two new COVID-19 antibody tests that are available in the U.S. and Europe. Continued to inc...
Thermo Fisher Scientific Increases Availability of COVID-19 Testing with Sample Collection Kit from Everlywell
Business

Thermo Fisher Scientific Increases Availability of COVID-19 Testing with Sample Collection Kit from Everlywell

WALTHAM, MA (STL.News) Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced it has received an expansion of its Emergency Use Authorization (EUA) for the TaqPath COVID-19 Combo Kit to include an additional sample collection method provided by Everlywell, a leading digital health testing company.  The TaqPath test is authorized for use with the Everlywell COVID-19 Test Home Collection Kit, which enables individuals to self-collect nasal swab specimens when determined by a healthcare provider to be appropriate based on results of a COVID-19 questionnaire. Samples collected using the Everlywell self-collection kit may be processed by CLIA-certified laboratories running Thermo Fisher's TaqMan SARS-CoV-2 RNase P Assay Kit, and the results obtained through th...
Thermo Fisher Scientific Further Expands COVID-19 Test Portfolio with Two New Antibody Tests
Business

Thermo Fisher Scientific Further Expands COVID-19 Test Portfolio with Two New Antibody Tests

WALTHAM, MA (STL.News) Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19 Total Antibody ELISA test, and the Thermo Scientific EliA SARS-CoV-2-Sp1 IgG test.  These new tests for detecting COVID-19 antibodies expand the company's leading response to the pandemic, which ranges from molecular diagnostic tests and sample collection products, to personal protective equipment, to support of therapy and vaccine development and manufacturing. "Thermo Fisher is committed to providing a range of innovative solutions, including new serology tests that complement our PCR-based tests," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. ...
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2020
Business

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2020

WALTHAM, MA (STL.News) Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter of 2020 before the market opens on Wednesday, October 21, 2020, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations.  To listen, call (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S.  The conference ID is 1570827.  You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com.  The earnings press release and related information can be found in that section of our website under "Financial Results."  A replay of the call will be available under "Web...
Thermo Fisher Scientific Reports Second Quarter 2020 Results
Business

Thermo Fisher Scientific Reports Second Quarter 2020 Results

WALTHAM, MA (STL.News) Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2020. Second Quarter 2020 Highlights Second quarter revenue increased 10% to $6.92 billion. Second quarter GAAP diluted earnings per share (EPS) increased 5% to $2.90. Second quarter adjusted EPS increased 28% to $3.89. Leveraged our industry-leading scale and expertise to meet strong global demand for COVID-19 products and services. Highlights in the second quarter included: Generated approximately $1.3 billion of COVID-related revenue Received expansion of emergency use authorization (EUA) to run our PCR test on additional instruments and consumables for greater workflow flexibility Designed and bu...
Thermo Fisher Scientific Declares Quarterly Dividend
Business

Thermo Fisher Scientific Declares Quarterly Dividend

WALTHAM, MA (STL.News) Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.22 per common share, payable on July 15, 2020, to shareholders of record as of June 15, 2020.
Official Statement from PerkinElmer in Response to Reuters Article
Business

Official Statement from PerkinElmer in Response to Reuters Article

Official Statement from PerkinElmer in Response to Reuters Article Published on May 18, 2020 WALTHAM, MA (STL.News) PerkinElmer, Inc. (NYSE: PKI) supports government efforts to identify and prevent abusive practices in healthcare.  PerkinElmer has received subpoenas from the government regarding investigations into third parties, and has fully cooperated with authorities and will continue to do so.  The Company is not aware of, and has not received any information regarding, wrongdoing by PerkinElmer, as implied by Reuters, nor does PerkinElmer have any information that the Company or any of our personnel are the target of a government investigation.
Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
Business

Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

WALTHAM, MA (STL.News) Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") announced today that it has priced an offering of $2.2 billion aggregate principal amount (the "Offering") of the following notes: $1.1 billion aggregate principal amount of its 4.133% senior notes due 2025, at the issue price of 100% of their principal amount, and $1.1 billion aggregate principal amount of its 4.497% senior notes due 2030, at the issue price of 100% of their principal amount. The Offering is expected to close on or about March 25, 2020, subject to customary closing conditions. The notes will pay interest on a semi-annual basis. Thermo Fisher intends to use the net proceeds of the Offering to pay a portion of the consideration for Thermo Fisher's previously announced acquisition of QI...
Thermo Fisher Scientific Declares Quarterly Dividend and Authorizes $2.5 Billion of Share Repurchases
Business

Thermo Fisher Scientific Declares Quarterly Dividend and Authorizes $2.5 Billion of Share Repurchases

(STL.News) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.19 per share.  The dividend will be paid on January 15, 2020, to shareholders of record as of December 17, 2019. The board also authorized the repurchase of $2.5 billion of shares of its common stock in the open market or in negotiated transactions.  The authorization has no expiration date.  This replaces the company's existing repurchase authorization, of which $500 million was remaining. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally.  Our mission is to enable ou...
Thermo Fisher Scientific Completes Acquisition of GSK Manufacturing Site in Cork, Ireland
General

Thermo Fisher Scientific Completes Acquisition of GSK Manufacturing Site in Cork, Ireland

Waltham, Mass., (STL.News) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of an active pharmaceutical ingredient (API) manufacturing facility from GlaxoSmithKline (GSK) for €90 million.  Completion of the transaction follows the receipt of all required regulatory approvals. Approximately 400 employees at the Cork, Ireland, site will become part of Thermo Fisher's Pharma Services business within its Laboratory Products and Services Segment. CLICK to VIEW SOURCE